Safe Zone in Trigger Point Injection

Launched by ANKARA UNIVERSITY · Oct 28, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Safe Zone in Trigger Point Injection," is studying a specific type of pain relief procedure for patients with Myofascial Pain Syndrome, which is a condition that causes muscle pain and discomfort. The main goal of the study is to find out the safest distance between the skin and the lung area (called the pleura) when performing trigger point injections. Researchers want to measure this distance in both sitting and lying down positions to help prevent any potential risks, like a rare but serious complication known as pneumothorax, which is when air leaks into the space around the lungs.

To participate in this study, patients need to be between the ages of 18 and 74 and must have a diagnosis of Myofascial Pain Syndrome. They should be scheduled for trigger point injections due to this condition. However, individuals with other serious health issues, active infections in the injection area, or known lung diseases will not be eligible. Participants can expect to undergo ultrasound imaging to measure distances safely during their procedure, contributing valuable information to improve patient safety in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients diagnosed with Myofascial Pain Syndrome
• • patients scheduled for trigger point injections due to Myofascial Pain Syndrome.
• Exclusion Criteria:
• • under 18 years of age,
• • additional diseases other than Myofascial Pain Syndrome,
• • the presence of active infection in the interscapular area where ultrasound imaging and measurements will be performed,
• • lesions that disrupt skin integrity or affect subcutaneous and muscle structures such as anomalies or masses that could impair imaging quality
• • individuals with known lung diseases
• • not consent to participate in the study."